

REMARKS


The specification has been amended to reflect the national stage status.

In addition, the claims have been amended to better conform to U.S. practice. Support for the pharmaceutically acceptable additive in claims 1 and 5 is found in the specification at page 29, lines 9-12.

Favorable action on the merit is solicited.

Respectfully submitted,

Toshikazu NAKAMURA et al.

By 
Warren M. Cheek, Jr.
Registration No. 33,367
Attorney for Applicants

WMC/dlk
Washington, D.C. 20006-1021
Telephone (202) 721-8200
Facsimile (202) 721-8250
March 1, 2006